{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-326821","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2025-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.071559+00:00","generated_at":"2026-05-16T12:35:17.685255+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Q32 Bio director Mark Iwicki withdraws resignation, remains Board Chair and committee member","bullets":["Mark Iwicki had previously notified intention to resign from Board effective Dec 31, 2025 to focus on CEO role at Inhibikase Therapeutics.","On Dec 17, 2025, Iwicki withdrew resignation with full Board support, effective immediately, citing reduced board commitments.","He will continue as Chair of the Board and Compensation Committee, and as a member of the Audit Committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-326821","json":"https://secwatch.observer/filing/0001193125-25-326821.json","markdown":"https://secwatch.observer/filing/0001193125-25-326821.md","text":"https://secwatch.observer/filing/0001193125-25-326821.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000119312525326821/0001193125-25-326821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000119312525326821/d29360d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:35:17.685255+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}